Stem cell-derived retinal cells need primary cilia to support survival of light-sensing photoreceptors
Scientists at the National Eye Institute (NEI), part of the National Institutes of Health, report that tiny tube-like protrusions called primary cilia on cells of the retinal pigment epithelium (RPE)—a layer of cells in the back of the eye—are essential for the survival of the retina’s light-sensing photoreceptors. The discovery has advanced efforts to make stem cell-derived RPE for transplantation into patients with geographic atrophy, otherwise known as dry age-related macular degeneration (AMD), a leading cause of blindness in the U.S. The study appears in the January 2 Cell Reports.
“We now have a better idea about how to generate and replace RPE cells, which appear to be among the first type of cells to stop working properly in AMD,” said the study’s lead investigator, Kapil Bharti, Ph.D., Stadtman investigator at the NEI. Bharti is leading the development of patient stem cell-derived RPE for an AMD clinical trial set to launch in 2018.
In a healthy eye, RPE cells nourish and support photoreceptors, the cells that convert light into electrical signals that travel to the brain via the optic nerve. RPE cells form a layer just behind the photoreceptors. In geographic atrophy, RPE cells die, which causes photoreceptors to degenerate, leading to vision loss.
Bharti and his colleagues are hoping to halt and reverse the progression of geographic atrophy by replacing diseased RPE with lab-made RPE. The approach involves using a patient’s blood cells to generate induced-pluripotent stem cells (iPSCs), cells capable of becoming any type of cell in the body. iPSCs are grown in the laboratory and then coaxed into becoming RPE for surgical implantation.
Attempts to create functional RPE implants, however, have hit a recurring obstacle: iPSCs programmed to become RPE cells have a tendency to get developmentally stuck, said Bharti. “The cells frequently fail to mature into functional RPE capable of supporting photoreceptors. In cases where they do mature, however, RPE maturation coincides with the emergence of primary cilia on the iPSC-RPE cells.”
The researchers tested three drugs known to modulate the growth of primary cilia on iPSC-derived RPE. As predicted, the two drugs known to enhance cilia growth significantly improved the structural and functional maturation of the iPSC-derived RPE. One important characteristic of maturity observed was that the RPE cells all oriented properly, correctly forming a single, functional monolayer. The iPSC-derived RPE cell gene expression profile also resembled that of adult RPE cells. And importantly, the cells performed a crucial function of mature RPE cells: they engulfed the tips of photoreceptor outer segments, a pruning process that keeps photoreceptors working properly.
By contrast, iPSC-derived RPE cells exposed to the third drug, an inhibitor of cilia growth, demonstrated severely disrupted structure and functionality.
As further confirmation of their observations, when the researchers genetically knocked down expression of cilia protein IFT88, the iPSC-derived RPE showed severe maturation and functional defects, as confirmed by gene expression analysis. Tissue staining showed that knocking down IFT88 led to reduced iPSC-derived RPE cell density and functional polarity, i.e., cells within the RPE tissue pointed in the wrong direction.
Bharti and his group found similar results in iPSC-derived lung cells, another type of epithelial cell with primary cilia. When iPSC-derived lung cells were exposed to drugs that enhance cilia growth, immunostaining confirmed that the cells looked structurally mature.
The report suggests that primary cilia regulate the suppression of the canonical WNT pathway, a cell signaling pathway involved in embryonic development. Suppression of the WNT pathway during RPE development instructs the cells to stop dividing and to begin differentiating into adult RPE, according to the researchers.
The researchers also generated iPSC-derived RPE from a patient with ciliopathy, a disorder that causes severe vision loss due to photoreceptor degeneration. The patient’s ciliopathy was associated with mutations of cilia gene CEP290. Compared to a healthy donor, iPSC-derived RPE from the ciliopathy patient had cilia that were smaller. The patient’s iPSC-derived RPE also had maturation and functional defects similar to those with IFT88 knockdown.
Further studies in a mouse model of ciliopathy confirmed an important temporal relationship: Looking across several early development stages, the RPE defects preceded the photoreceptor degeneration, which provides additional insights into ciliopathy-induced retinal degeneration.
Learn more: NIH discovery brings stem cell therapy for eye disease closer to the clinic
The Latest on: Dry age-related macular degeneration
[google_news title=”” keyword=”dry age-related macular degeneration” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- CIRM awards $31 million to fund clinical-stage research for cancers and eye diseaseon April 26, 2024 at 8:39 am
South San Francisco, CA, April 26, 2024 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has approved awarding ...
- Local group helps macular degeneration patients cope with vision losson April 26, 2024 at 3:07 am
To provide opportunity for encouragement, Phoenix-based Associated Retina Consultants, in coordination with the International Low Vision Support Group, has established a Macular Degeneration Support ...
- BCI maker Science acquires retinal implant from Pixium Visionon April 25, 2024 at 12:54 pm
Brain-computer interface developer Science Corporation acquired the IP and related assets for the Pixium Vision Prima implant.
- People over State Pension age with eyesight issues could be due up to £434 each monthon April 24, 2024 at 11:32 pm
Attendance Allowance could help people who are severely short-sighted or have eye conditions including cataract, glaucoma or macular degeneration.
- AMD STOPPER Offers New Hope to Sufferers of Age-Related Macular Degenerationon April 23, 2024 at 9:50 am
AMD Stopper Inc. is a newly organized company which holds the formulas, patent applications, and intellectual property rights to the formula developed by an eye care researcher to treat Age-Related ...
- Dry Age-related Macular Degeneration Seven Major Market to Exhibit Growth at a CAGR of 19.8% by 2034 | DelveInsighton April 22, 2024 at 2:31 pm
DelveInsight's Dry Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment practices, dry age-related macular degeneration marketed drug, ...
- Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Valueon April 19, 2024 at 2:05 pm
Ocugen is gearing up to report results from the two phase 1/2 studies for the treatment of patients with GA and Stargardt Disease. Check out why OCGN stock is a buy.
- Age-related Vision Dysfunction Market Size in the 7MM is anticipated to increase by 2032, estimates DelveInsighton April 17, 2024 at 3:06 pm
The increase in Age-related Vision Dysfunction Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM. As per DelveInsight ...
- InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degenerationon April 16, 2024 at 5:00 am
Small molecule drug acting as a preferential signaling ligand for CB1/CB2 Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical ...
- Driving at night can get harder starting as early as your late 20s. Here’s how to improve nighttime vision.on April 11, 2024 at 12:13 pm
As we get older, nighttime driving can become more challenging, thanks to age-related eye conditions. Here, eye care specialists explain the common causes of vision problems through the years, as well ...
via Google News and Bing News
2 Comments
Sadie
My dad is 78 he has lost his sight due to dry macular degeneration. Where or how can we get him treatment? He wants his life back so badly.
innovation
Suggest you contact the National Eye Institute and go from there. Good luck!